Pharma Can Meet Cancer Patients’ and Oncologists’ Unique COVID-19 Needs

Posted by Jon Roffman on Mar 25, 2020 10:30:20 AM

Prashant Poddar co-wrote this blog post with Jon Roffman.

Access COVID-19 resources

As the SARS-CoV-2 pandemic rages on, questions remain about how the virus is transmitted between people, how quickly it spreads and how contagious it is. But one thing is certain: The elderly and immunosuppressed patient populations, including those with cancer, are among the most at risk.

These patients need oncology manufacturers, healthcare providers and other stakeholders to ensure that they have continued access to care while minimizing exposure to the virus. Together, we can play a critical role in helping to improve and extend the lives of oncology patients. This should be our central focus today, knowing that it likely will change the way that we approach tomorrow and beyond.


>
Read More

Oncology 2020: From Invention to Outcomes

Posted by Jon Roffman on Mar 12, 2020 8:03:05 AM

Pranav Srivastava co-wrote this blog post with Jon Roffman. 

In the last three years alone, the FDA has given the green light to nearly 50 new cancer drugs. Were excited to see what 2020 has in store for this sector, as biopharma companies continue to bring these novel therapies and diagnostics to market. The fast pace of innovation in the oncology market presents increasingly complex challenges to manufacturers seeking to maximize the benefit that they can deliver to patientsWe’re committed to helping our client partnerand their customers thrive and ultimately improve outcomes for cancer patientsWith that in mind, our oncology practice is focused on three core dimensions that will be central to oncology manufacturers in the year ahead: navigating clinical pathways that drive the majority of treatment decisions in oncology; leveraging AI to deliver more relevant and valuable information to customers at the point of care; and delivering solutions that help customers better support their patients.


>
Read More

Precision Medicine Comes Into View With the Use of Next-Generation Sequencing

Posted by Jon Roffman on Jun 27, 2018 8:00:00 AM

Marie Yurkovich and Olivia Tang-Kong co-authored this post with Jon Roffman.

Precision medicine in cancer care has been anticipated and talked about for years. The ability to classify a patient based on her tumor’s molecular changes and then treat her with the right targeted therapy is a concept that gives hope to the many men, women and children diagnosed with cancer. Given recent advancements, there’s good reason for this hope.


>
Read More

Attention Oncology Manufacturers: Customer Experience Matters

Posted by Jon Roffman on Apr 4, 2016 8:00:00 AM

What’s the experience that we want our customers to have? It’s a simple question, really, so why isn’t it front and center for marketing and sales people at oncology companies? Perhaps because being in the business of providing life-extending medicines to cancer patients, we would believe that should result in a positive customer experience. We’d at least expect an experience that’s better than, say, the next iPhone or a visit to the Magic Kingdom, and yet when you look at the Net Promoter Score for oncology manufacturers, the experience that they deliver lags woefully behind that of Apple and Disney. In fact, based on a recent research study conducted by ZS, we see that most oncology manufacturers have a negative Net Promoter Score, meaning that more of their customers have a negative experience than a positive one.


>
Read More